Issue Date | Title | Author(s) |
2015-06 | Association of the CYP2C19 *2 allele on the occurrence of in-stent restenosis in patients undergoing coronary stenting | Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Barbara, Christopher; Fenech, Albert; Azzopardi, Lilian M. |
2015-10 | Comparison between a point-of-care and a laboratory-based CYP2C19*2 genotyping assay for pharmacist-led personalisation of antiplatelet therapy | Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Barbara, Christopher; Fenech, Albert; Azzopardi, Lilian M. |
2019-02 | CYP2C19 genetic polymorphisms in Maltese patients on clopidogrel therapy | Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Barbara, Christopher; Camilleri, Liberato; Fenech, Albert; Azzopardi, Lilian M. |
2021 | CYP2C19* 2 genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel : a matched case-control study | Osama, Sara; Wirth, Francesca; Zahra, Graziella; Barbara, Christopher; Xuereb, Robert G.; Camilleri, Liberato; Azzopardi, Lilian M. |
2018 | CYP2C19*2 allele carrier status and coronary in-stent restenosis : is there an association? | Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Barbara, Christopher; Camilleri, Liberato; Fenech, Albert; Azzopardi, Lilian M. |
2020 | CYP2C19*2 genetic polymorphism and other predictors for coronary in-stent restenosis in patients on clopidogrel therapy | Osama, Sara; Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Azzopardi, Lilian M. |
2012 | Dual antiplatelet therapy in percutaneous coronary intervention managed acute coronary syndrome patients | Gonzi, Anna |
2015-06 | Pharmacist-led CYP2C19 genotyping in patients on clopidogrel therapy following percutaneous coronary intervention | Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Barbara, Christopher; Fenech, Albert; Azzopardi, Lilian M. |
2016-03 | Pharmacist-led rapid point-of-care CYP2C19 genotyping for individualisation of antiplatelet therapy | Wirth, Francesca; Xuereb, Robert G.; Fenech, Albert; Azzopardi, Lilian M. |
2015 | Pharmacogenetic implications in clopidogrel therapy : a pharmacist-Ied management approach | Wirth, Francesca |
2015-10 | Point-of-care CYP2C19 genotyping in patients prescribed clopidogrel therapy following a percutaneous coronary intervention | Wirth, Francesca; Xuereb, Robert G.; Fenech, Albert; Azzopardi, Lilian M. |
2015-09 | Prevalence of the CYP2C19 *2 allele in Maltese patients on clopidogrel therapy | Wirth, Francesca; Zahra, Graziella; Xuereb, Robert G.; Barbara, Christopher; Fenech, Albert; Azzopardi, Lilian M. |
2005 | Randomized clinical trial of the antiplatelet effects of aspirin–clopidogrel combination versus aspirin alone after lower limb angioplasty | Cassar, Kevin; Ford, Isobel; Greaves, Mike; Bachoo, Paul; Brittenden, Julie |
2017-01 | Rapid point-of-care CYP2C19*2 genotyping to personalise antiplatelet therapy in patients undergoing coronary stenting | Wirth, Francesca; Xuereb, Robert G.; Fenech, Albert; Azzopardi, Lilian M. |
2006 | Variability in responsiveness to clopidogrel in patients with intermittent claudication | Cassar, Kevin; Bachoo, Paul; Ford, Isobel; Greaves, Michael; Brittenden, Julie |